AuraSeq uses next-generation sequencing (NGS) technology enabling the testing of multiple biomarkers, such as somatic variants in oncogenic driver genes, in a single assay.
We utilize the most accurate and up-to-date testing platforms and methodologies, under the guidance of our COVID-19 Task Force, to best detect and prevent the spread of COVID-19 in our communities.
This site uses cookies to improve user experience and performance. By continuing to use this site you consent to our use of cookies. For more information, please view our Privacy Policy.